Enhancing cellular cancer vaccines

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 495-504

  Cohen, Edward P ^a   Chopra, Amla ^a   O Sullivan, Insug ^a   Kim, Tae Sung ^b  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Korea University   (South Korea)

Author keywords

Cancer vaccine; Dendritic cell; DNA vaccine; Enriched vaccine; Fibroblast; Leukapheresis; Tumor DNA

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPSTEIN BARR VIRUS ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 2; MUCIN 1;

BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CYTOKINE PRODUCTION; DNA IMMUNIZATION; FIBROBLAST; HOUSEKEEPING GENE; HUMAN; IMMUNOPHARMACOLOGY; LEUKAPHERESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; GENETIC ENGINEERING; GENOMIC LIBRARY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MICE; VACCINES, DNA;

EID: 77953406214     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.4     Document Type: Review

References (62)

1. Emens LA: Towards a therapeutic breast cancer vaccine: the next steps. Expert Rev. Vaccines 4, 831-841 (2005).
2. Hahn T, Alvarez I, Kobie JJ, Ramanathapuram K, Dial S, Fulton T: Short-term dietary administration of celecoxib enhances the efficacy of tumor lysate-pulsed dendritic cell vaccines in treating murine breast cancer. Int. J. Cancer 118, 2220-2231 (2006).
3. Curigliano G, Spitaleri G, Pietri E et al.: Breast cancer vaccines: a clinical reality or fairy tale? Ann. Oncol. 17, 750-762 (2006).
4. Sauer G, Kurzeder C, Heilmann V, Kreienberg R, Deissler H: Immunotherapy and cancer vaccines in the management of breast cancer. Curr. Pharm. Des. 11, 3475-3483 (2005).
5. Jager D. Knuth A: Antibodies and vaccines - hope or illusion? Breast 14, 631-635 (2005).
6. Zhou J, Zhong Y: Breast cancer immunotherapy. Cell Mol. Immunol. 4, 247-255 (2004).
7. Wang X, Wang JP, Rao XM, Price JE, Zhou HS, Lachman LB: Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu* metastatic breast cancer in mice. Breast Cancer Res. 7, 580-588 (2005).
8. Peoples GE, Gurney JM, Hueman MT et al.: Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J. Clin. Oncol. 23, 7536-7545 (2005).
9. Ridgeway D. The first 1000 dendritic cell vaccines. Cancer Invest. 21, 873-886 (2003).
10. Wilkie S, Picco G, Foster J et al.: Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J. Immunol. 180, 4901-4909 (2008).
11. Carr-Brendel V, Markovic D, Ferrer K, Smith M, Taylor-Papadimitriou J, Cohen EP: Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res. 60, 2435-2443 (2000). (Pubitemid 30262434)
12. Guckel B, Rentzsch C, Nastke MD, Marme A, Gruber I, Stevanovic S: Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers. J. Cancer Res. Clin. Oncol. 22, 1-10 (2005).
13. + T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37). Expert Opin. Biol. Ther. 9, 71-78 (2009).
14. Sloots A, Mastini C, Rohrbach F et al.: DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/neu-driven mammary carcinoma. Clin. Cancer Res. 14, 6933-6943 (2008).
15. Paulsen JE, Bjørheim J, Røe J, Eide TJ, Alexander J, Gaudernack G.: Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane. Anticancer Res. 22, 171-175 (2002). (Pubitemid 34475293)
16. Ahlquist T, Lind GE, Costa VL et al.: Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes Cancer. 48, 1-9 (2009).
17. Sweeney C, Boucher KM, Samowitz WS et al.: Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes Cancer 48, 1-9 (2009).
18. Subramanya D, Grivas PD: HPV and cervical cancer: updates on an established relationship. Postgrad. Med.120, 7-13 (2008).
19. de Vos van Steenwijk PJ, Piersma SJ, Welters MJ et al.: Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. Clin. Cancer Res. 15(14), 7188-7195 (2008).
20. Stanley M: Immunobiology of HPV and HPV vaccines. Gynecol. Oncol. 109(Suppl. 2), S15-S21 (2008).
21. + T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Sci. 99, 1633-1642 (2008).
22. Lockey TD, Zhan X, Surman S, Sample CE, Hurwitz J: Epstein-Barr virus vaccine development: a lytic and latent protein cocktail. Front Biosci. 13, 5916-5927 (2008).
23. Rickinson AB: Immune intervention against virus-associated human cancers. Ann. Oncol. 6(Suppl. 1), 69-71 (1995).
24. Khanna R, Burrows SR, Kurilla MG et al.: Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176, 169-176 (1992).
25. Gnjatic S, Wheeler C, Ebner M et al.: Seromic analysis of antibody responses in non-small cell lung cancer patients and healthy donors using conformational protein arrays. J. Immunol. Methods 341(1-2), 50-58 (2009).
26. Jin S, Wang Y, Zhang Y et al.: Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity. Cancer Sci. 99, 1670-1678 (2008).
27. Ishida T, Obata Y, Ohara N et al.: Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun. 13, 8-15 (2008).
28. Geng L, Deepak P A, Aija L et al.: Identification of metastasis associated antigen 1 (MTA1) by serological screening of prostate cancer cDNA libraries. Biochem. J. 2, 100-107 (2008).
29. Ge W, Li Y, Li ZS et al.: The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following peroral administration route. Cancer Immunol. Immunother. 58, 201-208 (2009).
30. van Baren N, Bonnet MC, Dréno B et al.: Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J. Clin. Oncol. 23, 9008-9021 (2005).
31. + T-cell immune response. Int. J. Cancer 109, 909-918 (2004).
32. Ishida T, Obata Y, Ohara N et al.: Identification of the HERV-K gag antigen in prostate cancer by SEREX using autologous patient serum and its immunogenicity. Cancer Immun. 8, 15 (2008).
33. Jin S, Wang Y, Zhang Y et al.: Humoral immune responses against tumor-associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity. Cancer Sci. 99, 1670-1680 (2008).
34. Dougan M, Dranoff G. Immune therapy for cancer. Annu. Rev. Immunol. 27, 83-117 (2009).
35. Geng L, Deepak P A, Aija L et al.: Identification of metastasis associated antigen 1 (MTA1) by serological screening of prostate cancer cDNA libraries. Open Biochem. J. 2, 100-107 (2008).
36. + regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J. Immunol. 181, 6955-6963 (2008).
37. Heithoff DM, Enioutina EY, Bareyan D, Daynes RA, Mahan MJ: Conditions that diminish myeloid-derived suppressor cell activities stimulate cross-protective immunity. Infect. Immun. 76, 5191-5199 (2008).
38. + T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol. Immunother. 57, 1493-1504 (2008).
39. Chopra A, O-Sullivan I, Carr J, Kim TS, Cohen EP: T-regulatory cells are relatively deficient in squamous carcinomas undergoing regression in mice immunized with a squamous carcinoma vaccine enriched for immunotherapeutic cells. Cancer Gene Ther. 14, 573-582 (2007). ■ In a mouse squamous carcinoma model system, this report describes the reduced presence of T-regulatory cells in the regressing tumors of mice immunized with a vaccine enriched for immunotherapeutic cells.
40. Salazar LG, Disis ML: Cancer vaccines: the role of tumor burden in tipping the scale toward vaccine efficacy. J. Clin. Oncol. 23, 7397-7408 (2005). ■ Describes the heightened efficacy of vaccines administered when the tumor burden is small.
41. Tuve S, Chen BM, Liu Y et al.: Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 67, 5929-15239 (2007). (Pubitemid 46985029)
42. Olson WC, Heston WD, Rajasekaran AK: Clinical trials of cancer therapies targeting prostate-specific membrane antigen. Rev. Recent Clin. Trials 2, 182-190 (2007).
43. Doehn C, Böhmer T, Kausch I, Sommerauer M, Jocham D: Prostate cancer vaccines: current status and future potential. BioDrugs 22, 71-84 (2008).
44. Durso RJ, Andjelic S, Gardner JP et al.: A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin. Cancer Res. 13, 3999-4008 (2007).
45. Todorova K, Zoubak S, Mincheff M, Kyurkchiev S: Biochemical nature and mapping of PSMA epitopes recognized by human antibodies induced after immunization with gene-based vaccines. Anticancer Res. 25, 4727-4732 (2005). (Pubitemid 41729537)
46. de Cerio AL, Inogés S. Future of idiotypic vaccination for B-cell lymphoma. Expert Rev. Vaccines 8, 43-50 (2009).
47. Houot R, Levy R: Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev. 23(3), 137-142 (2009).
48. Reinis M: BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.Curr. Opin. Mol. Ther. 10, 526-534 (2008).
49. Qiu J, Lil GW, Sui YF, Sun YJ, Huang YY, Si SY: Truncated TERT mRNA transfected dendritic cells evoke TERT specific anti tumor response in vivo. Hepatogastroenterology 54, 681-687 (2007). (Pubitemid 46908461)
50. Mockey M, Bourseau E, Chandrashekhar V, Chaudhuri A, Lafosse S, Le Cam E: mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes. Cancer Gene Ther. 14, 802-814 (2007).
51. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30, 749-761 (2007). ■ Including allogeneic MHC determinants in a hybrid cell-tumor vaccine induced a therapeutic antitumor immune response in patients with renal cell cancer.
52. Hsu C, Kavathas P, Herzenberg LA: Cell surface antigens expressed on L cells transfected with whole DNA from non-expressing and expressing cells. Nature 312, 68-69 (1984). (Pubitemid 14010265)
53. Kavathas P, Herzenberg LA: Stable transformation of mouse LM cells (a transformed fibroblast cell line) for human membrane T-cell differentiation antigens, HLA and B2 microglobulin: selection by fluorescence-activated cell sorting. Proc. Natl Acad. Sci. USA 80, 524-528 (1983).
54. Shih C, Weinberg RA: Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 29, 161-169 (1982).
55. Shih C, Shilo B-Z, Goldfarb MP, Dannenberg A, Weinberg RA: Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc. Natl Acad. Sci. USA 76, 5714-5718 (1979).
56. Kim TS, Jung M, Cho D, Cohen EP: Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells. Vaccine 24, 6564-6573 (2006). (Pubitemid 44511856)
57. Kim TS, Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res. 54, 2531-2535 (1994). ■■ Original report of therapeutic efficacy of a cellular vaccine prepared by transfection of an allogeneic fibroblast cell line with DNA from melanoma cells.
58. Kim TS, Kim K-M, Shin BA, Hwang SY: Efficient induction of antigen-specific T helper type 1 immune response by interleukin-12-secreting fibroblasts. Immunology 100, 203-208 (2000).
59. Chung SW, Cohen EP, Kim TS: Generation of tumor-specific cytotoxic T lymphocytes and prolongation of survival of tumor-bearing mice with IL-18-secreting fibroblasts pulsed with an epitope peptide. Vaccine 22, 2547-2557 (2000).
60. Sung Kim T, Cohen EP: Immunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells. Cancer Gene. Ther. 12, 890-899 (2005). ■■ Describes the positive therapeutic results of cDNA-based vaccines in mice with breast cancer prepared from tumors less than 4 mm.
61. Kim TS, Chopra A, O-Sullivan I, Martinez D, Cohen EP: Immunity to breast cancer in mice immunized with a unique DNA-based vaccine: enrichment of the vaccine for cells that express breast cancer antigens. J. Immunother. 29, 261-273 (2006).
62. Chopra A, Kim TS, O-Sullivan I, Cohen EP: Immunity to squamous carcinoma in mice treated with a DNA-based vaccine enriched for cells that express squamous carcinoma antigens - a new vaccination strategy. Int. J. Cancer 119, 339-348 (2006). ■■ Primary report describing application of the enrichment strategy outlined in this review for the generation of a vaccine for treatment of mice with squamous cell carcinoma.